Home
Search

Press Releases

Get the latest on BIO’s announcements, positions, and views.

Featured Press Releases
BIO Statement on Veto of Prescription Drug…
Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB)…
Learn more
BIO Statement on Resignation of FDA Commissioner…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the resignation of FDA Commissioner Marty Makary.“Dr. Makary inherited an FDA in crisis after the DOGE…
Learn more
BIO Launches “The Fight of Our Lives,” a National…
WASHINGTON, DC – Today, the Biotechnology Innovation Organization (BIO) announced the launch of ​​The Fight of Our Lives, a new national campaign focused on the stories behind biotechnology breakthroughs, the patients whose lives depend on them…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
BIO Statement on USTR Special 301 Report
April 29, 2022
 USTR this week released its 2022 Special 301 Report. BIO, after reviewing the report, released the following statement: We welcome USTR’s efforts to address IP-related concerns for U.S.-based biotech enterprises in China, especially…
New Ways & Means health package a "critical building block for future biotech innovation"
April 19, 2022
In an effort to secure medical supply chains and invest in the cures and treatment of the future, members of the House Ways and Means committee this week reintroduced major legislation that "ensures a healthier future for all Americans." BIO…
CMS Decision is an Enormous Setback for Alzheimer's Patients and a Dangerous Infringement on FDA's Scientific Autonomy
April 7, 2022
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS’s) National Coverage Determination (NCD) to…
New Season of Biotech Podcast Builds Trust in Science
March 22, 2022
Washington, D.C.– The Biotechnology Innovation Organization (BIO) today premieres its new season of the I AM BIO podcast, which tells powerful stories across the biotechnology industry and how it heals, fuels, and feeds our world. The season…
BIO Statement on Reports of a Proposed Deal on COVID-19 Vaccine IP Rights Waiver
March 15, 2022
John Murphy, Chief Policy Officer at the Biotechnology Innovation Organization (BIO), released the following statement regarding reports of a proposed deal on a Covid-19 vaccine intellectual property rights waiver: “While we have seen the reported…
BIO Statement on Russia's Decision To Legalize Patent Theft
March 11, 2022
“Retaliation of this kind will only serve to isolate Russian science and technology from the international mainstream. At the end of the day those who will be most hurt by this decision will not be innovative global companies, but Russian patients,…
BIO Joins Efforts to Aid in Humanitarian Relief in Ukraine
March 2, 2022
The following statement can be attributed to BIO’s President and CEO Dr. Michelle McMurry-Heath in response to the ongoing conflict in Ukraine and the organization’s efforts to help in humanitarian relief: “The conflict in Ukraine and violence…
BIO Encourages Science-based Oversight for Animal and Plant Biotech as Dr. Califf Takes Helm at FDA
February 15, 2022
The following statement may be attributed to BIO's Vice President for Agriculture and Environment Sarah Gallo:  “BIO looks forward to working with a proven leader like Dr. Califf as he takes the helm at FDA. Dr. Califf will lead an…
BIO Statement on Confirmation of Dr. Califf to Lead FDA
February 15, 2022
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), made the following statement after Dr. Robert Califf was confirmed by the Senate to lead the Food and Drug Administration (FDA): “We congratulate Dr…
New BIO Report Examines the State of Antibacterial Innovation
February 14, 2022
Current pipeline “insufficient” to meet the threat of AMR, policy reforms critically needed   The Biotechnology Innovation Organization (BIO) today released a new report examining antibacterial innovation and the current pipeline for new…